Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Kala Pharmaceuticals, Inc. is not a good value stock. Kala Pharmaceuticals, Inc. is not very popular among insiders. Kala Pharmaceuticals, Inc. is a mediocre stock to choose.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercial...

News

Oppenheimer 'encouraged' by Kala Pharmaceuticals trial progress

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Globe Newswire ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...\n more…

Kala Pharmaceuticals price target lowered by $3 at H.C. Wainwright, here's why

KALA Stock Earnings: Kala Bio Beats EPS for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nKALA stock results show that Kala Bio beat analyst estimates for earnings per share the second quarter of 2024.\nThe post KALA Stock...\n more…

KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Globe Newswire -- Closed $12.5 million private placement financing led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor -- Cash resources of $54.2 million as...\n more…